AFFIMED N.V. news, videos and press releases
For more news please use our advanced search feature.
AFFIMED N.V. - More news...
AFFIMED N.V. - More news...
- Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
- Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
- Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
- Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
- Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
- Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
- Affimed Reports Third Quarter 2024 Financial Results & Business Update
- Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
- Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
- Affimed to Present at the Cantor Global Healthcare Conference 2024
- Affimed Reports Second Quarter 2024 Financial Results & Business Update
- Affimed Appoints Shawn M. Leland as Chief Executive Officer
- Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
- Affimed Reports First Quarter 2024 Financial Results & Business Update
- Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
- Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
- Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
- Affimed Announces Annual General Meeting of Shareholders
- Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
- Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
- Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
- Affimed Reports 2023 Financial Results and Operational Progress
- Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
- Affimed Announces 1-for-10 Reverse Stock Split
- Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
- Affimed Announces Leadership Change and Organizational Restructuring
- Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
- Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
- Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
